These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14673814)

  • 1. An empirical comparison of EQ-5D and SF-6D in liver transplant patients.
    Longworth L; Bryan S
    Health Econ; 2003 Dec; 12(12):1061-7. PubMed ID: 14673814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring health-related utility: why the disparity between EQ-5D and SF-6D?
    Bryan S; Longworth L
    Eur J Health Econ; 2005 Sep; 6(3):253-60. PubMed ID: 15968563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
    McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
    J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
    Whitehurst DG; Norman R; Brazier JE; Viney R
    Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
    Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
    Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
    Petrou S; Hockley C
    Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D.
    Sach TH; Barton GR; Doherty M; Muir KR; Jenkinson C; Avery AJ
    Int J Obes (Lond); 2007 Jan; 31(1):189-96. PubMed ID: 16682976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unchained melody: revisiting the estimation of SF-6D values.
    Craig BM
    Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
    Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
    Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease.
    van Stel HF; Buskens E
    Health Qual Life Outcomes; 2006 Mar; 4():20. PubMed ID: 16563170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-adjusted life expectancies in patients with rheumatoid arthritis--comparison of index scores from EQ-5D, 15D, and SF-6D.
    Sørensen J; Linde L; Ostergaard M; Hetland ML
    Value Health; 2012; 15(2):334-9. PubMed ID: 22433765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and empirical comparison of contemporaneous EQ-5D and SF-6D group mean scores.
    Whitehurst DG; Bryan S; Lewis M
    Med Decis Making; 2011; 31(6):E34-44. PubMed ID: 21993430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the EQ-5D and the SF-6D utility measures in 813 patients with early arthritis: results from the ESPOIR cohort.
    Gaujoux-Viala C; Rat AC; Guillemin F; Flipo RM; Fardellone P; Bourgeois P; Fautrel B
    J Rheumatol; 2011 Aug; 38(8):1576-84. PubMed ID: 21532054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
    Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
    Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
    Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
    Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EQ-5D versus SF-12 in coronary patients: are they interchangeable?
    De Smedt D; Clays E; Annemans L; De Bacquer D
    Value Health; 2014; 17(1):84-9. PubMed ID: 24438721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
    Stepanova M; Nader F; Cure S; Bourhis F; Hunt S; Younossi ZM
    Aliment Pharmacol Ther; 2014 Sep; 40(6):676-85. PubMed ID: 25040192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.
    Joore M; Brunenberg D; Nelemans P; Wouters E; Kuijpers P; Honig A; Willems D; de Leeuw P; Severens J; Boonen A
    Value Health; 2010; 13(2):222-9. PubMed ID: 19878492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.